Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies酪氨酸激酶抑制剂的AI建模及其在吸收不良风险下的生物利用度提升策略British Journal of Clinical PharmacologyIF32025-07-080PRE
Exploring the contribution of genetic variants to high sunitinib exposure in patients with cancerBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32024-08-061OA
Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancerBMC CANCERIF3.42022-03-0214OAAI
Excessive toxicity of cabozantinib in a phase II study in patients with recurrent and/or metastatic salivary gland cancerEUROPEAN JOURNAL OF CANCERIF7.12022-01-0113OA
Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancerINTERNATIONAL JOURNAL OF CANCERIF4.72021-09-168OAAI
Exposure-response analysis of cabozantinib in patients with metastatic renal cell cancer treated in routine careANNALS OF ONCOLOGYIF65.42021-09-010OAAI
The impact of a 1-hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposureINTERNATIONAL JOURNAL OF CANCERIF4.72021-01-1910OAAI
The relationship between sunitinib exposure and both efficacy and toxicity in real-world patients with renal cell carcinoma and gastrointestinal stromal tumourBRITISH JOURNAL OF CLINICAL PHARMACOLOGYIF32020-05-2622OAAI
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced NeuropathyCLINICAL CANCER RESEARCHIF10.22016-10-0241OAAI